Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 2Vipoma 1Somatostatinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × motesanib diphosphate × Clear all
NCT00574951 2018-01-11

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Terminated
23 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡